PIK3CA H1047R mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-PIK3CA-H1047R |
|---|---|
| Type | Biomarker |
| Aliases | PIK3CA H1047RМутація PIK3CA H1047R |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"exon": "20", "functional_impact": "activating (kinase-domain hotspot; constitutive PI3K signalling)", "gene": "PIK3CA", "hgvs_protein": "p.H1047R", "variant_type": "missense"} |
| Measurement | MethodTumor-tissue NGS panel OR ctDNA (FoundationOne Liquid CDx, Guardant) |
| Actionability lookup | {"gene": "PIK3CA", "variant": "H1047R"} |
| Related biomarkers | BIO-PIK3CA-MUTATION BIO-ESTROGEN-RECEPTOR |
Notes
~40% of breast cancer carries PIK3CA mutation; H1047R and E545K are the two dominant hotspots (~50% and ~25% respectively). SOLAR-1 trial (André 2019, NEJM): alpelisib + fulvestrant doubled PFS vs fulvestrant alone in HR+/HER2- PIK3CA-mut MBC post-AI. INAVO120 (inavolisib) — next-gen PI3Kα inhibitor 1L. Capivasertib (AKT-i) also active in PIK3CA/AKT1/PTEN-altered (CAPItello-291). Hyperglycaemia AE common — baseline HbA1c required.
Used By
No reverse references found in the YAML corpus.